Key Highlights

  • Revenue was USD 5.65 million against an estimate of USD 27.75 million.
  • Loss per share was USD 0.12 against estimated Earnings of USD 0.004.
  • Net loss was USD 12.54 million, compared with USD 19.73 million.
  • Research and development expenses were USD 14.83 million, compared with USD 21.71 million.

Prelude Therapeutics (NASDAQ:PRLD) reported Revenue of USD 5.65 million for the third quarter of 2026, compared with USD 6.50 million in the prior-year quarter, against an estimate of USD 27.75 million. Net loss per share was USD 0.12, compared with USD 0.26, against estimated earnings of USD 0.004.

The net loss was USD 12.54 million, compared with USD 19.73 million. For the nine months ended September 30, 2026, revenue was USD 15.93 million, compared with USD 6.50 million, and the net loss was USD 36.85 million, compared with USD 83.04 million.

Operating Expenses

Research and development expenses were USD 14.83 million, compared with USD 21.71 million, and general and administrative expenses were USD 5.08 million, compared with USD 5.21 million. Total operating expenses were USD 19.91 million, compared with USD 26.92 million.

The loss from operations was USD 14.27 million, compared with USD 20.42 million, and other income, net, was USD 1.72 million, compared with USD 693 thousand.

Nine-Month Results

For the nine months, Research and Development expenses were USD 44.56 million, compared with USD 76.31 million, and general and administrative expenses were USD 15.27 million, compared with USD 17.41 million. Total operating expenses were USD 59.83 million, compared with USD 93.72 million.

The loss from operations was USD 43.90 million, compared with USD 87.22 million, and other income, net, was USD 7.05 million, compared with USD 4.18 million. Net loss per share for the nine months was USD 0.39, compared with USD 1.09.

Cash and Marketable Securities

Cash and cash equivalents were USD 23.41 million at September 30, 2026, compared with USD 35.26 million at December 31, 2025, and marketable securities were USD 116.59 million, compared with USD 67.96 million. Total Assets were USD 175.49 million, compared with USD 141.32 million.

The filing states that cash, cash equivalents, restricted cash and marketable securities totaled USD 142.7 million at September 30, 2026, and that the company believes these funds are sufficient to fund operating expenses and Capital Expenditure requirements for at least the next twelve months from the filing date. The filing reports net proceeds of approximately USD 85.4 million from its April offering, after deducting Underwriting discounts, commissions and offering expenses of approximately USD 4.6 million.

The filing states that in March 2023 the company entered into an Open Market Sales Agreement with Jefferies LLC as sales agent, and that the pre-funded warrants sold in the April offering had not been exercised as of September 30, 2026. The filing directs readers to its note on the exclusive option agreement and collaboration agreements for a full discussion of its revenue contracts.

Prepaid expenses and other current assets were USD 2.43 million, compared with USD 2.48 million. Weighted average common shares outstanding, basic and diluted, were approximately 103 million for the quarter.

Prelude Therapeutics Q3 2026 Earnings: Key Takeaways

Prelude Therapeutics reported third quarter 2026 revenue of USD 5.65 million and a net loss of USD 12.54 million. Cash, cash equivalents, restricted cash and marketable securities totaled USD 142.7 million at September 30, 2026.